Given the context-dependent tumor-promoting and -suppressing roles of SIK2, administration of SIK2 inhibitors in GPCR-mutated or other overactive cAMP-PKA cancer types should be attempted with extremely caution to avoid potential pro-tumor effects. This evidence concerns the gene SIK2 and neoplasm.